Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Should Oncologists Recommend Cannabis?

Authors: Donald I. Abrams
Current Treatment Options in Oncology, 3 June 2019

Cannabis is a useful botanical with a wide range of therapeutic potential. Global prohibition over the past century has impeded the ability to study the plant as medicine. However, delta-9-tetrahydrocannabinol (THC) has been developed as a stand-alone pharmaceutical initially …

Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.

Authors: Stephanie McGrath, Lisa R. Bartner, Sangeeta Rao, Rebecca A. Packer, Daniel L. Gustafson
Journal of the American Veterinary Medical Association, 1 June 2019

OBJECTIVE: To assess the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy. DESIGN: Randomized blinded controlled clinical trial. ANIMALS: 26 client-owned dogs with intracta…

Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.

Authors: Thangam Venkatesan, David J. Levinthal, B U. K. Li, Sally E. Tarbell, Kathleen A. Adams, et al
Neurogastroenterology and Motility, June 2019

Cannabis is commonly used in cyclic vomiting syndrome (CVS) due to its antiemetic and anxiolytic properties. Paradoxically, chronic cannabis use in the context of cyclic vomiting has led to the recognition of a putative new disorder called cannabinoid hyperemesis syndrome (CHS…

A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.

Authors: Elizabeth Steels, Ruchitha Venkatesh, Eleanor Steels, Gemma Vitetta, Luis Vitetta
Inflammopharmacology, June 2019

BACKGROUND: The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis. METHODS: This was a single site, comparative, double-blind placebo controlled study i…

Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome.

Authors: Shira Hirsch, Joseph Tam
Toxins, 15 May 2019

In this review, we discuss the role of the endocannabinoid (eCB) system in regulating energy and metabolic homeostasis. Endocannabinoids, via activating the cannabinoid type-1 receptor (CB1R), are commonly known as mediators of the thrifty phenotype hypothesis due to their act…

Anti-tumour actions of cannabinoids.

Authors: Burkhard Hinz, Robert Ramer
British Journal of Pharmacology, May 2019

The endocannabinoid system has emerged as an important target for the treatment of many diverse diseases. In addition to the well-established palliative effects of cannabinoids in cancer therapy, phytocannabinoids, synthetic cannabinoid compounds and inhibitors of endocannabin…

Species-specific susceptibility to cannabis-induced convulsions.

Authors: Benjamin J. Whalley, Hong Lin, Lynne Bell, Thomas Hill, Amesha Patel, Roy A. Gray, C. Elizabeth Roberts, Orrin Devinsky, Michael Bazelot, Claire M. Williams, Gary J. Stephens Published in…

Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications.

Authors: Arulkumar Nagappan, Jooyeon Shin, Myeong Ho Jung
International Journal of Molecular Sciences, 29 April 2019

Endogenous cannabinoids (ECs) are lipid-signaling molecules that specifically bind to cannabinoid receptor types 1 and 2 (CB1R and CB2R) and are highly expressed in central and many peripheral tissues under pathological conditions. Activation of hepatic CB1R is associated with…

Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting.

Authors: Tiffany N. Smith, Anne Walsh, Christopher P. Forest
Journal of the American Academy of Physician Assistants, April 2019

Cannabis has long been used for medical and recreational purposes because of its antiemetic, analgesic, and mood effects. Ironically, chronic use of cannabis can result in paradoxical effects, including a condition known as cannabinoid hyperemesis syndrome. Patients with this …

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

Practical Perspectives in the Treatment of Nausea and Vomiting.

Authors: David J. Cangemi, Braden Kuo
Journal of Clinical Gastroenterology, March 2019

Nausea and vomiting result from complex interactions between afferent and efferent pathways of the gastrointestinal tract, central nervous system, and autonomic nervous system. Afferent pathways from the vagus nerve, vestibular system, and chemoreceptor trigger zone project to…

Women’s perspectives about cannabis use during pregnancy and the postpartum period: An integrative review.

Authors: Hamideh Bayrampour, Mike Zahradnik, Sarka Lisonkova, Patti Janssen
Preventive Medicine, February 2019

Cannabis is the most commonly used illicit drug among general and pregnant populations. Despite recommendations to abstain from cannabis use, its use is increasing during the perinatal period. In this integrative review, we aim to understand women’s perspectives about the heal…